One question on HIV prevention: Will patients take their meds?

Patients who know they're sick have trouble sticking to their medication regimens, as anyone who works to boost drug adherence knows. So, can people at risk of HIV infection be trusted to continue taking high-powered antiretrovirals to keep from getting the disease? News | Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.